Trials / Completed
CompletedNCT06018441
A Study to Evaluate the Quality of Life in Male and Female Adult Participants With Severe Asthma Treated With Dupilumab in a Real-world Setting
National, Multicenter, Non-interventional, Prospective Study to Explore the Quality of Life of Patients With Severe Asthma Starting Treatment With Dupilumab (Dupixent®) in a Real-world Setting
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 112 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Primary Objective: \- To describe dupilumab health-related quality of life (HRQoL) effectiveness at 52 weeks compared to baseline. Secondary Objectives: * To describe dupilumab HRQoL effectiveness at 12 and 24 weeks compared to baseline. * To assess the safety during the year of treatment in a real-world setting.
Conditions
Timeline
- Start date
- 2023-10-03
- Primary completion
- 2025-10-10
- Completion
- 2025-10-10
- First posted
- 2023-08-30
- Last updated
- 2025-12-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06018441. Inclusion in this directory is not an endorsement.